Modalis Therapeutics Corporation (JP:4883) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Modalis Therapeutics Corporation has announced a strategic plan to prioritize their leading AAV therapeutics program and restructure their U.S. subsidiary, leading to a reduction of operating expenses by downsizing personnel. The company is focusing on obtaining IND clearance for their MDL-101 clinical trial and expects these changes to reduce expenses by 35-40 million yen for the fiscal year ending December 31, 2024.
For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.